May 25, 2023 · History of ADC Development The idea of targeted chemotherapy was conceptualized by a German scientist, Paul Ehrlich, over a century ago. His magic bullet would target a cytotoxin to intended structures in unwanted cells but spare healthy tissues. 1 The structures were later conceptualized to be cell surface antigens to attract antibodies that ...

May 3, 2023 · Before there was a way to digitize the analog world around us and then reproduce it, life was very different. So how did we get here? The answer lies in the history of analog to digital converters. Communication. This human imperative was the impetus behind the invention of the analog-to-digital converter (ADC).

Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [1] . Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs. [2]

Aug 30, 2018 · History and development of ADCs. In 1913, Paul Ehrlich, a German physicist and scientist, was the first to propose the concept of targeted delivery of toxic agents against microbes or tumor...

Nov 1, 2024 · Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs.

Nov 22, 2019 · In 1913, German physicist and scientist Paul Ehrlich pioneered the concept of targeted delivery of toxic agents against microbes or tumor cells. After nearly forty years of research, ADC has achieved promising results in clinical trials.

Apr 14, 2023 · In this article, we will explore the history of ADCs, from their early development to the latest advances in technology and applications. We will also discuss the current state of the field and the future outlook of antibody drug conjugates, with a focus on ADC manufacturing.

Feb 10, 2021 · To understand the renewed hype around ADCs, let’s look back at their history and consider what the future may hold for these targeted therapies. In the early 1900s, German scientist Paul Ehrlich theorized that a ‘magic bullet’ drug could be developed that selectively targeted a disease-causing organism with a toxin.

Jan 1, 2015 · Since this book focuses on recent developments of ADC with recombinant monoclonal antibodies, this chapter only covers the early history of ADC development from the late 1960s to early 1980s, i.e., during pre- and early post-monoclonal antibody era.

Aug 20, 2020 · After the rapid development of monoclonal antibody drugs in the past 10 years and more effective small molecular anticancer drugs have been discovered, the Second-generation ADC drugs have better CMC properties than the First-generation ADC drugs.